PTGS2 and hepatocellular carcinoma: These findings revealed a fundamental PKA/SHP2-dependent negative feedback loop acting on JAK/STAT signaling, and inhibition of this signaling by the selective COX2 inhibitors may enhance the clinical efficacy of type I IFNs in treating HCC.